Emerging nanotherapeutic strategies in breast cancer

Breast

Volumn 23, Issue 1, 2014, Pages 10-18

  Blanco, Elvin ^a   Ferrari, Mauro ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Breast cancer; Chemotherapy; Liposomes; Nanoparticle drug delivery; Polymer micelles

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; LAPATINIB; LIPOSOME; NANOPARTICLE; NC 6004; PACLITAXEL; POLYMER; RAPAMYCIN; SP 1049C; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLERGIC REACTION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG REPOSITIONING; DRUG TOLERABILITY; HUMAN; MOLECULARLY TARGETED THERAPY; MYALGIA; NEUROPATHY; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; STOMATITIS; TUMOR GROWTH; TUMOR INVASION;

BREAST CANCER; CHEMOTHERAPY; LIPOSOMES; NANOPARTICLE DRUG DELIVERY; POLYMER MICELLES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; MICELLES; NANOPARTICLES; PACLITAXEL; POLYMERS; RNA INTERFERENCE;

EID: 84890875776     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.10.006     Document Type: Review

References (94)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. Peto R., Davies C., Godwin J., Gray R., Pan H.C., Clarke M., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379(9814):432-444.
3. Smith L.A., Cornelius V.R., Plummer C.J., Levitt G., Verrill M., Canney P., et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010, 10:337.
4. Hagiwara H., Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer 2004, 11(1):82-85.
5. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. JControl Release 2012, 160(2):117-134.
6. Schmidt C. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear. JNatl Cancer Inst 2011, 103(2):87-89.
7. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEngl J Med 2011, 365(14):1273-1283.
8. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
9. McAuliffe P.F., Meric-Bernstam F., Mills G.B., Gonzalez-Angulo A.M. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010, 10(Suppl.3):S59-S65.
10. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9(1):16-32.
11. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011, 16(Suppl.1):12-19.
12. Petrocca F., Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. JClin Oncol 2011, 29(6):747-754.
13. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5(3):161-171.
14. Mattheolabakis G., Rigas B., Constantinides P.P. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond) 2012, 7(10):1577-1590.
15. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6(4):715-728.
16. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63(3):131-135.
17. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011, 6(12):815-823.
18. Harrington K.J., Syrigos K.N., Vile R.G. Liposomally targeted cytotoxic drugs for the treatment of cancer. JPharm Pharmacol 2002, 54(12):1573-1600.
19. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4(2):145-160.
20. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8(2):129-138.
21. Gregoriadis G., Davis C. Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells. Biochem Biophys Res Commun 1979, 89(4):1287-1293.
22. Sawant R.R., Torchilin V.P. Challenges in development of targeted liposomal therapeutics. AAPS J 2012, 14(2):303-315.
23. Hamilton A., Biganzoli L., Coleman R., Mauriac L., Hennebert P., Awada A., et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann Oncol 2002, 13(6):910-918.
24. Volkova M., Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011, 7(4):214-220.
25. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15(3):440-449.
26. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94(1):25-36.
27. Sparano J.A., Makhson A.N., Semiglazov V.F., Tjulandin S.A., Balashova O.I., Bondarenko I.N., et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. JClin Oncol 2009, 27(27):4522-4529.
28. Venturini M., Bighin C., Puglisi F., Olmeo N., Aitini E., Colucci G., et al. Amulticentre phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast 2010, 19(5):333-338.
29. Cortes J., Di Cosimo S., Climent M.A., Cortes-Funes H., Lluch A., Gascon P., et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res 2009, 15(1):307-314.
30. Hernandez-Aya L.F., Gonzalez-Angulo A.M. Adjuvant systemic therapies in breast cancer. Surg Clin North Am 2013, 93(2):473-491.
31. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. JClin Oncol 2003, 21(6):976-983.
32. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993, 20(4 Suppl 3):1-15.
33. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006, 7(8):1041-1053.
34. Yamamoto Y., Kawano I., Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 2011, 4:123-136.
35. Miele E., Spinelli G.P., Miele E., Tomao F., Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99-105.
36. Surapaneni M.S., Das S.K., Das N.G. Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol 2012, 2012:623139.
37. Paal K., Muller J., Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 2001, 268(7):2187-2191.
38. Yang G., Truong L.D., Timme T.L., Ren C., Wheeler T.M., Park S.H., et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998, 4(8):1873-1880.
39. Hawkins M.J., Soon-Shiong P., Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008, 60(8):876-885.
40. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8(5):1038-1044.
41. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006, 12(4):1317-1324.
42. Sparreboom A., Scripture C.D., Trieu V., Williams P.J., De T., Yang A., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol). Clin Cancer Res 2005, 11(11):4136-4143.
43. Gardner E.R., Dahut W.L., Scripture C.D., Jones J., Aragon-Ching J.B., Desai N., et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008, 14(13):4200-4205.
44. Nyman D.W., Campbell K.J., Hersh E., Long K., Richardson K., Trieu V., et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. JClin Oncol 2005, 23(31):7785-7793.
45. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. JClin Oncol 2005, 23(31):7794-7803.
46. Blanco E., Kessinger C.W., Sumer B.D., Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 2009, 234(2):123-131.
47. Cabral H., Nishiyama N., Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res 2011, 44(10):999-1008.
48. Xiong X.B., Falamarzian A., Garg S.M., Lavasanifar A. Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery. JControl Release 2011, 155(2):248-261.
49. Sutton D., Nasongkla N., Blanco E., Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007, 24(6):1029-1046.
50. Wang J., Mongayt D., Torchilin V.P. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity invitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. JDrug Target 2005, 13(1):73-80.
51. Zhou K., Wang Y., Huang X., Luby-Phelps K., Sumer B.D., Gao J. Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. Angew Chem Int Ed Engl 2011, 50(27):6109-6114.
52. Cheng Y., Hao J., Lee L.A., Biewer M.C., Wang Q., Stefan M.C. Thermally controlled release of anticancer drug from self-assembled gamma-substituted amphiphilic poly(epsilon-caprolactone) micellar nanoparticles. Biomacromolecules 2012, 13(7):2163-2173.
53. Wan C.P., Jackson J.K., Pirmoradi F.N., Chiao M., Burt H.M. Increased accumulation and retention of micellar paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure. Ultrasound Med Biol 2012, 38(5):736-744.
54. Nasongkla N., Bey E., Ren J., Ai H., Khemtong C., Guthi J.S., et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 2006, 6(11):2427-2430.
55. Hrkach J., Von Hoff D., Mukkaram Ali M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4(128):128ra39.
56. Nurunnabi M., Cho K.J., Choi J.S., Huh K.M., Lee Y.K. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials 2010, 31(20):5436-5444.
57. Wilson R.H., Plummer R., Adam J., Eatock M.M., Boddy A.V., Griffin M., et al. Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles. JClin Oncol 2008, 26(15).
58. Valle J.W., Lawrance J., Brewer J., Clayton A., Corrie P., Alakhov V., et al. Aphase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus. JClin Oncol 2004, 22(14). 362S-362S.
59. Burris H.A., Infante J.R., Spigel D.R., Greco F.A., Thompson D.S., Matsumoto S., et al. Aphase I dose-escalation study of NK012. JClin Oncol 2008, 26(15).
60. Kim T.Y., Kim D.W., Chung J.Y., Shin S.G., Kim S.C., Heo D.S., et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004, 10(11):3708-3716.
61. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., et al. Multicenter phase II trial of genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108(2):241-250.
62. Park J.W., Hong K.L., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002, 8(4):1172-1181.
63. Drummond D.C., Noble C.O., Guo Z., Hayes M.E., Connolly-Ingram C., Gabriel B.S., et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. JControl Release 2010, 141(1):13-21.
64. Spector N.L., Xia W., Burris H., Hurwitz H., Dees E.C., Dowlati A., et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. JClin Oncol 2005, 23(11):2502-2512.
65. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. JClin Oncol 2010, 28(7):1124-1130.
66. Gao H., Cao S., Chen C., Yang Z., Pang Z., Xi Z., et al. Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and antitumor effect in breast cancer. Nanomedicine (Lond) 2013, 8(9):1429-1442.
67. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004, 10(20):7031-7042.
68. Gonzalez-Angulo A.M., Green M.C., Murray J.L., Palla S.L., Koenig K.H., Brewster A.M., et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). JClin Oncol 2011, 29(Suppl). abstr 1016.
69. Shi P., Aluri S., Lin Y.-A., Shah M., Edman M., Dhandhukia J., Cui H., MacKay J.A. Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth invivo. JControl Release 2013, 171(3):330-338.
70. Moreno-Aspitia A. Clinical overview of sorafenib in breast cancer. Future Oncol 2010, 6(5):655-663.
71. Tran M.A., Smith C.D., Kester M., Robertson G.P. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 2008, 14(11):3571-3581.
72. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669):806-811.
73. Pirollo K.F., Rait A., Zhou Q., Hwang S.H., Dagata J.A., Zon G., et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007, 67(7):2938-2943.
74. Gao Z., Zhang L., Sun Y. Nanotechnology applied to overcome tumor drug resistance. JControl Release 2012, 162(1):45-55.
75. Yin Q., Shen J., Chen L., Zhang Z., Gu W., Li Y. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters). Biomaterials 2012, 33(27):6495-6506.
76. Cochran M.C., Eisenbrey J., Ouma R.O., Soulen M., Wheatley M.A. Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery. Int J Pharm 2011, 414(1-2):161-170.
77. Puri A., Kramer-Marek G., Campbell-Massa R., Yavlovich A., Tele S.C., Lee S.B., et al. HER2-specific affibody-conjugated thermosensitive liposomes (affisomes) for improved delivery of anticancer agents. JLiposome Res 2008, 18(4):293-307.
78. Gao Z.G., Tian L., Hu J., Park I.S., Bae Y.H. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. JControl Release 2011, 152(1):84-89.
79. Tasciotti E., Liu X., Bhavane R., Plant K., Leonard A.D., Price B.K., et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol 2008, 3(3):151-157.
80. Ferrari M. Beyond drug delivery. Nat Nanotechnol 2008, 3(3):131-132.
81. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol 2010, 28(4):181-188.
82. Decuzzi P., Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 2008, 29(3):377-384.
83. Decuzzi P., Pasqualini R., Arap W., Ferrari M. Intravascular delivery of particulate systems: does geometry really matter?. Pharm Res 2009, 26(1):235-243.
84. Chiappini C., Tasciotti E., Fakhoury J.R., Fine D., Pullan L., Wang Y.C., et al. Tailored porous silicon microparticles: fabrication and properties. Chemphyschem 2010, 11(5):1029-1035.
85. Ananta J.S., Godin B., Sethi R., Moriggi L., Liu X., Serda R.E., et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol 2010, 5(11):815-821.
86. Shen H., You J., Zhang G., Ziemys A., Li Q., Bai L., et al. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater 2012, 1(1):84-89.
87. Serda R.E., Mack A., Pulikkathara M., Zaske A.M., Chiappini C., Fakhoury J., et al. Cellular association and assembly of a multistage delivery system. Small 2010, 6(12):1329-1340.
88. Shen H.F., Rodriguez-Aguayo C., Xu R., Gonzalez-Villasana V., Mai J.H., Huang Y., et al. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res 2013, 19(7):1806-1815.
89. Tanaka T., Mangala L.S., Vivas-Mejia P.E., Nieves-Alicea R., Mann A.P., Mora E., et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010, 70(9):3687-3696.
90. Blanco E., Sangai T., Hsiao A., Ferrati S., Bai L., Liu X., et al. Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett 2013, 334(2):245-252.
91. van de Ven A.L., Kim P., Haley O.H., Fakhoury J.R., Adriani G., Schmulen J., et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. JControl Release 2012, 158(1):148-155.
92. Decuzzi P., Godin B., Tanaka T., Lee S.Y., Chiappini C., Liu X., et al. Size and shape effects in the biodistribution of intravascularly injected particles. JControl Release 2010, 141(3):320-327.
93. Godin B., Chiappini C., Srinivasan S., Alexander J.F., Yokoi K., Ferrari M., et al. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice. Adv Funct Mater 2012, 22(20):4225-4235.
94. Xu R., Huang Y., Mai J., Zhang G., Guo X., Xia X., et al. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small 2013, 9(9-10):1799-1808.